{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:50Z","timestamp":1792601090445,"version":"4.5.0"},"reference-count":31,"publisher":"MyJove Corporation","issue":"207","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/66407","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T20:00:41Z","timestamp":1716667241000},"source":"Crossref","is-referenced-by-count":2,"title":["Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma"],"prefix":"10.3791","author":[{"given":"Qiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangshou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"issue":"24","key":"ref1","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.21037\/atm-21-6020","type":"journal-article","article-title":"Molecular mechanism of CK19 involved in the regulation of postoperative recurrence of HBV-associated primary hepatocellular carcinoma in Guangxi","volume":"9","author":"Su","year":"2021","unstructured":"Su, H. et al. Molecular mechanism of CK19 involved in the regulation of postoperative recurrence of HBV-associated primary hepatocellular carcinoma in Guangxi. Ann Transl Med. 9 (24), 1780 (2021).","journal-title":"Ann Transl Med"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","type":"journal-article","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","unstructured":"Zheng, R. et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2 (1), 1-9 (2022).","journal-title":"J Natl Cancer Center"},{"issue":"3","key":"ref3","first-page":"209","type":"journal-article","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 71 (3), 209-249 (2021).","journal-title":"CA"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","type":"journal-article","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","unstructured":"Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.). 67 (1), 358-380 (2018).","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1055\/a-1111-8666","type":"journal-article","article-title":"A prospective study of fully covered metal stents for different types of refractory benign biliary strictures","volume":"52","author":"Sato","year":"2020","unstructured":"Sato, T. et al. A prospective study of fully covered metal stents for different types of refractory benign biliary strictures. Endoscopy. 52 (5), 368-376 (2020).","journal-title":"Endoscopy"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5582\/bst.2021.01091","type":"journal-article","article-title":"Conversion therapy and maintenance therapy for primary hepatocellular carcinoma","volume":"15","author":"Zhou","year":"2021","unstructured":"Zhou, H., Song, T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 15 (3), 155-160 (2021).","journal-title":"Biosci Trends"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamasurg.2018.4334","type":"journal-article","article-title":"Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma","volume":"154","author":"Xu","year":"2019","unstructured":"Xu, X. F. et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma. JAMA Surg. 154 (3), 209-217 (2019).","journal-title":"JAMA Surg"},{"issue":"10","key":"ref8","first-page":"4711","type":"journal-article","article-title":"The past, present, and future of conversion therapy for liver cancer","volume":"11","author":"Song","year":"2021","unstructured":"Song, T., Lang, M., Ren, S., Gan, L., Lu, W. The past, present, and future of conversion therapy for liver cancer. Am J Cancer Res. 11 (10), 4711-4724 (2021).","journal-title":"Am J Cancer Res"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/COC.0b013e3181df0a50","type":"journal-article","article-title":"Radioembolization for hepatocellular carcinoma: A review of the evidence and treatment recommendations","volume":"34","author":"Sangro","year":"2011","unstructured":"Sangro, B., Salem, R., Kennedy, A., Coldwell, D., Wasan, H. Radioembolization for hepatocellular carcinoma: A review of the evidence and treatment recommendations. Am J Clin Oncol. 34 (4), 422 (2011).","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"ref10","first-page":"486","type":"journal-article","article-title":"Expert consensus on the standardized procedure of selective internal radiation therapy with Yttrium-90 microspheres for liver malignancies (2024 edition)","volume":"104","year":"2024","unstructured":"Chinese Medical Doctor Association, Clinical Guidelines Committee of Chinese College of Interventionalists, Chinese Research Hospital Association, Society for Hepatopancreatobiliary Surgery. Expert consensus on the standardized procedure of selective internal radiation therapy with Yttrium-90 microspheres for liver malignancies (2024 edition). Zhonghua Yi Xue Za Zhi. 104 (7), 486-498 (2024).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","type":"journal-article","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","unstructured":"Vilgrain, V. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 18 (12), 1624-1636 (2017).","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref12","first-page":"10100","type":"journal-article","article-title":"Safety and efficacy of concurrent Atezolizumab\/Bevacizumab or Nivolumab combination therapy with Yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma","volume":"30","author":"Villalobos","year":"2023","unstructured":"Villalobos, A. et al. Safety and efficacy of concurrent Atezolizumab\/Bevacizumab or Nivolumab combination therapy with Yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma. Curr Oncol (Toronto, Ont.). 30 (12), 10100-10110 (2023).","journal-title":"Curr Oncol (Toronto, Ont.)"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.21980","type":"journal-article","article-title":"Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis","volume":"47","author":"Kulik","year":"2008","unstructured":"Kulik, L.M. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (Baltimore, Md.). 47 (1), 71-81 (2008).","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1102\/1470-7330.2013.0057","type":"journal-article","article-title":"Yttrium-90 radioembolization of liver tumors: what do the images tell us","volume":"13","author":"Singh","year":"2013","unstructured":"Singh, P., Anil, G. Yttrium-90 radioembolization of liver tumors: what do the images tell us? Cancer Imaging. 13 (4), 645 (2013).","journal-title":"Cancer Imaging"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s13139-010-0047-7","type":"journal-article","article-title":"Radiation safety issues in Y-90 microsphere selective hepatic radioembolization therapy: Possible radiation exposure from the patients","volume":"44","author":"Kim","year":"2010","unstructured":"Kim, Y. C. et al. Radiation safety issues in Y-90 microsphere selective hepatic radioembolization therapy: Possible radiation exposure from the patients. Nuc Med Mol Imag. 44 (4), 252-260 (2010).","journal-title":"Nuc Med Mol Imag"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijrobp.2006.11.060","type":"journal-article","article-title":"Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium","volume":"68","author":"Kennedy","year":"2007","unstructured":"Kennedy, A. et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiation Oncol, Biol, Phys. 68 (1), 13-23 (2007).","journal-title":"Int J Radiation Oncol, Biol, Phys"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0035-1564704","type":"journal-article","article-title":"Yttrium-90 radioembolization of hepatocellular carcinoma-performance, technical advances, and future concepts","volume":"32","author":"Molvar","year":"2015","unstructured":"Molvar, C., Lewandowski, R. Yttrium-90 radioembolization of hepatocellular carcinoma-performance, technical advances, and future concepts. Semin Intervent Radiol. 32 (4), 388-397 (2015).","journal-title":"Semin Intervent Radiol"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/cancers15030733","type":"journal-article","article-title":"Liver resection and transplantation following Yttrium-90 radioembolization for primary malignant liver tumors: A 15-year single-center experience","volume":"15","author":"Aliseda","year":"2023","unstructured":"Aliseda, D. et al. Liver resection and transplantation following Yttrium-90 radioembolization for primary malignant liver tumors: A 15-year single-center experience. Cancers. 15 (3), 733 (2023).","journal-title":"Cancers"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00270-018-1993-1","type":"journal-article","article-title":"Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma","volume":"41","author":"Wehrenberg-Klee","year":"2018","unstructured":"Wehrenberg-Klee, E., Goyal, L., Dugan, M., Zhu, A.X., Ganguli, S. Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma. Cardiovas Intervent Radiol. 41 (11), 1799-1802 (2018).","journal-title":"Cardiovas Intervent Radiol"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00270-023-03391-4","type":"journal-article","article-title":"Predictive factors for adverse event outcomes after transarterial radioembolization with Yttrium-90 resin microspheres in Europe: Results from the prospective observational CIRT study","volume":"46","author":"Maleux","year":"2023","unstructured":"Maleux, G. et al. Predictive factors for adverse event outcomes after transarterial radioembolization with Yttrium-90 resin microspheres in Europe: Results from the prospective observational CIRT study. Cardiovas Intervent Radiol. 46 (7), 852-867 (2023).","journal-title":"Cardiovas Intervent Radiol"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","type":"journal-article","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","unstructured":"Lencioni, R., Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30 (1), 52-60 (2010).","journal-title":"Semin Liver Dis"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"e0288","DOI":"10.1097\/HC9.0000000000000288","type":"journal-article","article-title":"Contemporary applications of Y90 for the treatment of hepatocellular carcinoma","volume":"7","author":"Yu","year":"2023","unstructured":"Yu, Q., Khanjyan, M., Fidelman, N., Pillai, A. Contemporary applications of Y90 for the treatment of hepatocellular carcinoma. Hepatol Comm. 7 (10), e0288 (2023).","journal-title":"Hepatol Comm"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000530495","type":"journal-article","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 Edition)","volume":"12","author":"Zhou","year":"2023","unstructured":"Zhou, J. et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 Edition). Liver Cancer. 12 (5), 405 (2023).","journal-title":"Liver Cancer"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1109\/TMI.2009.2022753","type":"journal-article","article-title":"Effect of voxel size and computation method on Tc-99m MAA SPECT\/CT-based dose estimation for Y-90 microsphere therapy","volume":"28","author":"Pasciak","year":"2009","unstructured":"Pasciak, A. S., Erwin, W. D. Effect of voxel size and computation method on Tc-99m MAA SPECT\/CT-based dose estimation for Y-90 microsphere therapy. IEEE Trans Med Imag. 28 (11), 1754-1758 (2009).","journal-title":"IEEE Trans Med Imag"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"772195","DOI":"10.3389\/fonc.2021.772195","type":"journal-article","article-title":"Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: An overview","volume":"11","author":"Sun","year":"2021","unstructured":"Sun, H. C., Zhu, X. D. Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: An overview. Front Oncol. 11, 772195 (2021).","journal-title":"Front Oncol"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","type":"journal-article","article-title":"90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: Results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","unstructured":"Dhondt, E. et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: Results from the TRACE phase II randomized controlled trial. Radiology. 303 (3), 699-710 (2022).","journal-title":"Radiology"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/cancers15030645","type":"journal-article","article-title":"For hepatocellular carcinoma treated with Yttrium-90 microspheres, dose volumetrics on post-treatment Bremsstrahlung SPECT\/CT predict clinical outcomes","volume":"15","author":"Taswell","year":"2023","unstructured":"Taswell, C.S. et al. For hepatocellular carcinoma treated with Yttrium-90 microspheres, dose volumetrics on post-treatment Bremsstrahlung SPECT\/CT predict clinical outcomes. Cancers. 15 (3), 645 (2023).","journal-title":"Cancers"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.4240\/wjgs.v13.i12.1550","type":"journal-article","article-title":"Neoadjuvant treatment strategies for hepatocellular carcinoma","volume":"13","author":"Xu","year":"2021","unstructured":"Xu, L., Chen, L., Zhang, W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointes Surg. 13 (12), 1550-1566 (2021).","journal-title":"World J Gastrointes Surg"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","type":"journal-article","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","unstructured":"Chew, V. et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 68 (2), 335-346 (2019).","journal-title":"Gut"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/jcmm.16256","type":"journal-article","article-title":"Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation","volume":"25","author":"Jiang","year":"2021","unstructured":"Jiang, Y. et al. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. J Cell Mol Med. 25 (3), 1568-1582 (2021).","journal-title":"J Cell Mol Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"612139","DOI":"10.3389\/fimmu.2021.612139","type":"journal-article","article-title":"TANK-binding kinase 1 (TBK1) serves as a potential target for hepatocellular carcinoma by enhancing tumor immune infiltration","volume":"12","author":"Jiang","year":"2021","unstructured":"Jiang, Y. et al. TANK-binding kinase 1 (TBK1) serves as a potential target for hepatocellular carcinoma by enhancing tumor immune infiltration. Front Immunol. 12, 612139 (2021).","journal-title":"Front Immunol"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/66407\/y-90-radioembolization-pd-1-inhibitor-as-neoadjuvant-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:25:33Z","timestamp":1792599933000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/66407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":31,"journal-issue":{"issue":"207","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3791\/66407","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]}}}